3Billion Inc

3Billion Inc has a strong liquidity position, with a current ratio of 6.23 and cash and equivalents of 8,142,114,540 KRW, indicating a robust short-term financial buffer. The company's debt-to-equity ratio is 0.14, suggesting a conservative capital structure with minimal leverage. However, the company reported negative operating and net income, with operating income of -5,889,097,930 KRW and net income of -5,411,302,060 KRW, reflecting ongoing operational losses. Profitability metrics are underperforming relative to industry norms. The company's return on equity (ROE) is -22.93%, and return on assets (ROA) is -18.24%, both significantly below the typical performance of firms in the biotechnology and medical research sector. These figures indicate that the company is not generating returns that meet the cost of capital or asset efficiency benchmarks. The company operates in a single business segment focused on genetic testing and related R&D, with no disclosed geographic diversification. Revenue is entirely concentrated in its core operations, and there is no indication of international revenue exposure in the latest financial data. Outlook for the current fiscal year is mixed. Analysts estimate revenue to reach 19,000,000,000 KRW, a 62.3% increase from the last reported revenue of 11,709,000,000 KRW. However, EBIT is expected to remain negative at -2,850,000,000 KRW, and EPS is projected to improve only slightly from -171.00 KRW to -66.00 KRW. Risk factors include ongoing operational losses and negative cash flows, with operating cash flow at -3,558,249,940 KRW and free cash flow at -5,772,427,970 KRW. The company has no immediate filing-based liquidity or dilution flags, and dilution risk is assessed as low. No recent equity issuance or dilutive events were identified in the latest filings. Recent financial filings and transcripts indicate a focus on R&D and scaling diagnostic services. The company is investing in technology to automate pathogenicity analysis, which could be a long-term growth driver. However, the current financial performance suggests that these investments have not yet translated into profitability.